Up to now, sequential stages of disease initiation and progression have been characterised at the molecular level by activating mutations in oncogenes (e.g. K-Ras) and functional inactivation of tumour-suppressor genes (e.g. P16, TP53 and DPC4) (Maitra and Hruban, 2008). Here, TP53 is linked to neoplasm.